ReViral is a technology company.
ReViral has raised $120.0M across 3 funding rounds.
ReViral has raised $120.0M in total across 3 funding rounds.
ReViral has raised $120.0M in total across 3 funding rounds.
ReViral's investors include Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston.
ReViral is not a technology company—it is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics.[1][3] The premise of your query contains an inaccuracy that should be clarified before proceeding with the requested analysis.
ReViral is a biotechnology company dedicated to discovering and developing novel antiviral therapies, with an initial focus on respiratory syncytial virus (RSV) treatment.[1][3] The company addresses a significant unmet medical need: RSV represents a major health concern for children, the elderly, and immunocompromised patients, creating a substantial commercial opportunity.[1]
The company's lead product candidate is sisunatovir, an orally administered fusion inhibitor that has demonstrated significant activity in Phase 2 clinical studies.[1][2] Sisunatovir significantly reduced viral load in a Phase 2 RSV human challenge study in healthy adults and was being evaluated in Phase 2 clinical development in infants.[3] ReViral also maintains a second program targeting RSV replication through N-protein inhibition, with a lead candidate in Phase 1 clinical development.[3]
ReViral was founded a decade before 2022 (approximately 2012) by Dr. Ken Powell and Dr. Stuart Cockerill, both bringing deep antiviral expertise to the venture.[3] The company emerged from a clear scientific mission: to develop world-class therapies for RSV patients, a virus that had long represented an underserved therapeutic area.[3]
The company achieved significant validation through multiple funding rounds. In August 2020, ReViral closed a $44 million Series C financing led by CR-CP Life Science Fund, demonstrating strong investor confidence in its clinical programs and management team.[2] This capital supported Phase 2 clinical development for sisunatovir and advancement of the N-protein replication inhibitor program into Phase 1 trials.[2]
In April 2022, Pfizer acquired ReViral in a definitive agreement, recognizing the company's promising therapeutic candidates and deep antiviral expertise.[3] At the time of the announcement, Pfizer projected that ReViral's programs could generate annual revenue of $1.5 billion or more, underscoring the commercial potential of its RSV pipeline.[5] CEO Alex Sapir characterized Pfizer as "an optimal partner given their commitment to RSV," highlighting the strategic fit between the companies' missions.[5]
Following this acquisition, ReViral's development programs were integrated into Pfizer's broader portfolio, which now includes Abrysvo, an RSV vaccine approved in 2023 as part of Pfizer's competitive position in the RSV market alongside Moderna's mResvia and GSK's Arexvy.[5]
ReViral has raised $120.0M across 3 funding rounds. Most recently, it raised $44.0M Series C in August 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2020 | $44.0M Series C | Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston | |
| Jul 1, 2018 | $55.0M Series B | Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston | |
| Sep 1, 2015 | $21.0M Series A | Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston |